Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed (INSM) has granted inducement awards to 30 new employees as part of their employment agreements. The awards consist of options to purchase a total of 64,240 shares of Insmed common stock at an exercise price of $72.42 per share, which was the closing price on the Nasdaq Global Select Market on the grant date of December 2, 2024.
The stock options have a 10-year term and follow a four-year vesting schedule: 25% vests after the first year, followed by 12.5% vesting every six months until the fourth anniversary, contingent on continued employment with Insmed.
Insmed (INSM) ha concesso premi di incentivazione a 30 nuovi dipendenti come parte dei loro contratti di lavoro. I premi consistono in opzioni per acquistare un totale di 64.240 azioni del comune di Insmed a un prezzo di esercizio di 72,42 $ per azione, che corrisponde al prezzo di chiusura del Nasdaq Global Select Market nella data di concessione, il 2 dicembre 2024.
Le opzioni azionarie hanno un termine di 10 anni e seguono un programma di maturazione di quattro anni: il 25% matura dopo il primo anno, seguito dal 12,5% che matura ogni sei mesi fino al quarto anniversario, a condizione di un impiego continuativo presso Insmed.
Insmed (INSM) ha otorgado premios de incentivo a 30 nuevos empleados como parte de sus contratos de trabajo. Los premios consisten en opciones para comprar un total de 64,240 acciones de acciones ordinarias de Insmed a un precio de ejercicio de 72.42 $ por acción, que fue el precio de cierre en el Nasdaq Global Select Market en la fecha de concesión del 2 de diciembre de 2024.
Las opciones sobre acciones tienen un plazo de 10 años y siguen un calendario de adquisición de cuatro años: el 25% se adquiere después del primer año, seguido del 12.5% que se adquiere cada seis meses hasta el cuarto aniversario, condicionado a la continuidad del empleo en Insmed.
Insmed (INSM)는 30명의 신입 사원에게 고용 계약의 일환으로 유인 보상을 제공합니다. 이 보상은 총 64,240주의 Insmed 보통주를 72.42달러의 행사 가격으로 구매할 수 있는 옵션으로 구성되어 있으며, 이는 2024년 12월 2일 보상 시점의 나스닥 글로벌 선택 시장에서의 종가입니다.
주식 옵션은 10년 기간을 가지고 있으며, 4년의 배정 일정을 따릅니다: 첫 해 후 25%가 배정되고, 이후 6개월마다 12.5%씩 배정되어 네 번째 기념일까지 계속됩니다. 이는 Insmed에서의 고용 지속성을 조건으로 합니다.
Insmed (INSM) a accordé des primes d'incitation à 30 nouveaux employés dans le cadre de leurs contrats de travail. Les primes consistent en des options d'achat d'un total de 64 240 actions d'actions ordinaires d'Insmed à un prix d'exercice de 72,42 $ par action, qui correspondait au prix de clôture sur le Nasdaq Global Select Market à la date d'attribution du 2 décembre 2024.
Les options d'achat d'actions ont une durée de 10 ans et suivent un calendrier d'acquisition de quatre ans : 25 % s'acquièrent après la première année, suivis de 12,5 % qui s'acquièrent tous les six mois jusqu'au quatrième anniversaire, sous réserve de la continuité de l'emploi chez Insmed.
Insmed (INSM) hat 30 neuen Mitarbeitern als Teil ihrer Arbeitsverträge Anreizvergaben gewährt. Die Vergaben bestehen aus Optionen zum Kauf von insgesamt 64.240 Aktien der Stammaktien von Insmed zu einem Ausübungspreis von 72,42 $ pro Aktie, was dem Schlusskurs am Nasdaq Global Select Market zum Zeitpunkt der Vergabe am 2. Dezember 2024 entspricht.
Die Aktienoptionen haben eine Laufzeit von 10 Jahren und folgen einem vierjährigen Vesting-Zeitplan: 25% werden nach dem ersten Jahr vestiert, gefolgt von 12,5%, die alle sechs Monate bis zum vierten Jubiläum vestiert werden, vorausgesetzt, das Arbeitsverhältnis mit Insmed bleibt bestehen.
- None.
- None.
In connection with the commencement of their employment, the employees received options on December 2, 2024 to purchase an aggregate 64,240 shares of Insmed common stock at an exercise price of
The options have a 10-year term and a four-year vesting schedule, with
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company's early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.
Headquartered in Bridgewater,
Contact:
Investors:
Bryan Dunn
Executive Director, Investor Relations
(646) 812-4030
bryan.dunn@insmed.com
Michael V. Morabito, Ph.D.
Director, Investor Relations
(917) 936-8430
michael.morabito@insmed.com
Gianna De Palma
Manager, Investor Relations
(873) 886-2236
gianna.depalma@insmed.com
Media:
Mandy Fahey
Vice President, Corporate Communications
(732) 718-3621
amanda.fahey@insmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302324022.html
SOURCE Insmed Incorporated
FAQ
How many shares were granted in Insmed's December 2024 inducement awards?
What is the exercise price for Insmed's (INSM) December 2024 inducement stock options?
What is the vesting schedule for Insmed's (INSM) December 2024 inducement stock options?
